Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$468M |
| 2 |
Johnson & Johnson
JNJ
|
+$440M |
| 3 |
IBM
IBM
|
+$355M |
| 4 |
Booking.com
BKNG
|
+$332M |
| 5 |
RAI
Reynolds American Inc
RAI
|
+$331M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LLTC
Linear Technology Corp
LLTC
|
+$482M |
| 2 |
Walt Disney
DIS
|
+$247M |
| 3 |
Visa
V
|
+$219M |
| 4 |
Deere & Co
DE
|
+$200M |
| 5 |
Johnson Controls International
JCI
|
+$179M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.02% |
| 2 | Technology | 13.31% |
| 3 | Financials | 12.25% |
| 4 | Industrials | 9.65% |
| 5 | Consumer Staples | 9.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2251
Helix Energy Solutions
HLX
$1.49B
| $1.96M | ﹤0.01% |
252,227
-4,700
| -2% | -$37.8K |
|
|
KDNY
2252
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.96M | ﹤0.01% |
36,380
+32,160
| +762% | +$1.82M |
|
2253
Cadiz
CDZI
$295M
| $1.94M | ﹤0.01% |
129,200
-138,200
| -52% | -$1.93M |
|
|
SMC
2254
Summit Midstream
SMC
$480M
| $1.94M | ﹤0.01% |
5,395
-7,093
| -57% | -$2.57M |
|
|
ACFC
2255
DELISTED
Atlantic Coast Financial Corporation
ACFC
| $1.94M | ﹤0.01% |
254,300
+15,200
| +6% | +$115K |
|
|
SPRT
2256
DELISTED
support.com, Inc.
SPRT
| $1.94M | ﹤0.01% |
882,463
+77,230
| +10% | +$173K |
|
|
ARI
2257
Apollo Commercial Real Estate
ARI
$886M
| $1.94M | ﹤0.01% |
+102,940
| New | +$1.83M |
|
2258
First Mid Bancshares
FMBH
$1.39B
| $1.94M | ﹤0.01% |
57,200
-13,400
| -19% | -$437K |
|
2259
Myers Industries
MYE
$1.25B
| $1.94M | ﹤0.01% |
122,100
+8,000
| +7% | +$114K |
|
|
RMP
2260
DELISTED
Rice Midstream Partners LP
RMP
| $1.94M | ﹤0.01% |
76,733
-75,726
| -50% | -$1.86M |
|
2261
The RMR Group
RMR
$346M
| $1.93M | ﹤0.01% |
39,000
-34,800
| -47% | -$1.65M |
|
2262
V2X
VVX
$2.55B
| $1.93M | ﹤0.01% |
86,400
+42,400
| +96% | +$973K |
|
2263
Insight Enterprises
NSIT
$4.6B
| $1.93M | ﹤0.01% |
+46,973
| New | +$1.92M |
|
|
HIL
2264
DELISTED
Hill International, Inc. Common Stock
HIL
| $1.93M | ﹤0.01% |
464,400
+1,800
| +0.4% | +$8.95K |
|
2265
iShares MSCI Mexico ETF
EWW
$1.87B
| $1.92M | ﹤0.01% |
+37,600
| New | +$1.74M |
|
2266
Peoples Financial Services
PFIS
$717M
| $1.92M | ﹤0.01% |
46,000
+200
| +0.4% | +$8.71K |
|
|
WBA
2267
DELISTED
Walgreens Boots Alliance
WBA
| $1.92M | ﹤0.01% |
23,100
-1,905,200
| -99% | -$160M |
|
2268
Pluri
PLUR
$17.9M
| $1.91M | ﹤0.01% |
19,423
+1,613
| +9% | +$158K |
|
|
NSH
2269
DELISTED
NuStar GP Holdings LLC
NSH
| $1.91M | ﹤0.01% |
68,300
+38,136
| +126% | +$1.13M |
|
2270
Daktronics
DAKT
$988M
| $1.9M | ﹤0.01% |
201,300
+78,500
| +64% | +$774K |
|
|
PFNX
2271
DELISTED
Pfenex Inc.
PFNX
| $1.89M | ﹤0.01% |
325,800
+194,700
| +149% | +$1.46M |
|
2272
CONMED
CNMD
$1.49B
| $1.89M | ﹤0.01% |
+42,481
| New | +$1.83M |
|
|
DWCH
2273
DELISTED
Datawatch Corp
DWCH
| $1.89M | ﹤0.01% |
224,600
+57,200
| +34% | +$409K |
|
2274
AMERISAFE
AMSF
$504M
| $1.88M | ﹤0.01% |
28,900
-10,500
| -27% | -$675K |
|
2275
Cumberland Pharmaceuticals
CPIX
$118M
| $1.88M | ﹤0.01% |
270,240
+13,240
| +5% | +$80.3K |
|
Similar funds
Jim Simons's Q1 2017 Portfolio in Review
As of Q1 2017, Jim Simons held 3,652 positions worth $71.6B, up 13% from $63.2B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
Jim Simons deployed $5.19B of net new capital in Q1 2017, opening 433 new positions and adding to 1,585 existing holdings. Its largest new stake was Merck: 7,716,460 shares worth $468M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 12% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Walt Disney, an estimated $247M trimmed.
- Jim Simons's largest Q1 2017 buy was Merck: 7,716,460 shares worth $468M.
- Jim Simons added most to Johnson & Johnson in Q1 2017, an estimated $440M increase.
- Jim Simons's biggest Q1 2017 reduction was Walt Disney, cutting an estimated $247M.
- Jim Simons fully exited Linear Technology Corp in Q1 2017, selling an estimated $482M.
- Jim Simons's ten largest holdings make up 7.9% of its $71.6B portfolio in Q1 2017.
- Jim Simons opened 433 new positions and closed 462 in Q1 2017.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $71.6B.
Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.